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Purpose. The interaction of hormones of the pituitary-adrenal axis and adrenal cortex-associated circulating microRNAs is mostly
unknown.We have studied the effects of dexamethasone and adrenocorticotropin on the expression of five circulating microRNAs
(hsa-miR-27a, hsa-miR-200b, hsa-miR-214, hsa-miR-483-5p, and hsa-miR-503) reported to be related to the adrenal cortex in plasma
samples. Methods. Expression of microRNAs was studied in plasma samples of 10 individuals examined by 1mg dexamethasone
suppression test and another 10 individuals stimulated by 250 𝜇g tetracosactide (adrenocorticotropin). Total RNA was isolated and
microRNA expression was analyzed by real-time reverse transcription quantitative polymerase chain reaction normalized to cel-
miR-39 as reference. Results. Only circulating hsa-miR-27a proved to be significantly modulated in vivo by hormonal treatments:
its expression was upregulated by dexamethasone whereas it was suppressed by adrenocorticotropin. Secreted hsa-miR-27a was
significantly induced by dexamethasone in vitro in NCI-H295R cells, as well. The expression of hsa-miR-483-5p proposed as
diagnosticmarker for adrenocortical malignancy was not affected by dexamethasone or tetracosactide administration.Conclusions.
hsa-miR-27a expression is modulated by hormones of the hypothalamic-pituitary-adrenal axis both in vitro and in vivo. The
biological relevance of hsa-miR-27a modulation by hormones is unclear, but the responsiveness of circulating microRNAs to
hormones of the pituitary-adrenal axis is noteworthy.
1. Introduction
MicroRNAs (miRNA, miR) are short nonprotein coding
RNA molecules involved in the posttranscriptional regula-
tion of gene expression as parts of the epigenetic machinery.
MicroRNAs were shown to be implicated in the regulation
of several basic homeostatic processes like cell proliferation,
apoptosis, development, immune regulation, hormone secre-
tion, and so forth, [1]. Alterations of tissuemicroRNAprofiles
have been described in a wide array of diseases, for example,
atherosclerosis, inflammatory diseases, and tumors [1–3].
Beside tissue microRNAs, novel data show that microRNAs
are released in the circulation by three main mechanisms: (i)
passive release from damaged cells (inflammation, necrosis),
or (ii) active release packed inmembrane vesicles (microvesi-
cles, exosomes, and apoptotic bodies), or (iii) active release in
complex with macromolecules like high density lipoprotein
or Argonaute proteins [4]. The physiological function of
circulating microRNAs is mostly unknown, but it is hypoth-
esized that they might act as hormones conveying epigenetic
information to distant tissues [5].
There are some data that the expression of tissue microR-
NAs is affected by hormones. Tissue microRNA profiles of
steroid-producing organs have been shown to be modulated
by treatment with hormones, for example, adrenocorti-
cotropin (ACTH), dexamethasone, and estradiol [6, 7].There
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are also findings showing that circulating microRNA levels
might also be influenced by hormone actions [8]. To the
best of our knowledge, the circulating microRNA levels after
administration of dexamethasone and ACTH affecting the
hypothalamic-pituitary-adrenal axis have not been studied in
humans in vivo, yet.
Adrenocortical cancer (ACC) is a rare tumor with an
incidence of 0.5–2/million/year. The preoperative diagnosis
of malignancy in adrenal tumors is very difficult. It is
rather difficult to establish malignancy in small tumors and
to exclude it in large adrenal tumors. Some circulating
microRNAbiomarkers, including hsa-miR-483-5p, have been
proposed as promisingmarkers ofmalignancy inACC [9–11].
Keeping in mind that during the evaluation of an adrenal
mass dexamethasone suppression and ACTH stimulation
tests are widely used diagnostic approaches, the question
might be raised whether the expression level of circulat-
ing microRNAs including proposed biomarkers for adreno-
cortical malignancies is affected during these functional
endocrine tests.
Our objective has been to study whether the expression of
selected circulatingmicroRNAs is affected by dexamethasone
and ACTH administration in vivo in plasma samples of
humans. We have included microRNAs used in the diagnosis
of adrenocortical cancer to assess whether their plasma levels
are affected by these treatments.
We have selected five microRNAs (hsa-miR-27a, hsa-
miR-200b, hsa-miR-214, hsa-miR-483-5p, and hsa-miR-503)
whose tissue counterparts were shown to be modulated
by ACTH or dexamethasone in an animal model (hsa-
miR-27a, hsa-miR-200b, hsa-miR-214, and hsa-miR-503) [7]
and/or involved in the pathogenesis of ACC (hsa-miR-214,
hsa-miR-483-5p, and hsa-miR-503) [9–11]. hsa-miR-483-5p is
overexpressed not only in the tissue of adrenal cancer but
also as a circulating microRNA in patient’s blood [9–11].
We have studied these selected microRNAs in altogether 20
individuals examined for hypercortisolism (Cushing’s syn-
drome) by low-dose dexamethasone test [12] and for adrenal
insufficiency or late onset congenital adrenal hyperplasia (21-
hydroxylase deficiency) by ACTH (tetracosactide) test [13].
2. Subjects and Methods
2.1. Patients. 10 patients were tested for suspected hypercor-
tisolism by low-dose overnight (1mg) dexamethasone sup-
pression test suffering from obesity, hirsutism, hypertension,
and adrenal incidentaloma. Another 10 patients have been
examined by 250 𝜇g tetracosactide (Cosyntropin, Sandoz
Inc.) for suspected Addison’s disease or late onset congenital
adrenal hyperplasia (deficiency of 21-hydroxylase) suffering
fromweakness, secondary oligomenorrhea, infertility, or hir-
sutism. Baseline cortisol was taken between 7.00 and 9.00 a.m.
in fasting condition. Dexamethasone was taken at 11.00 pm,
and bloodwas drawn the nextmorning between 7.00 and 9.00
a.m. Blood was taken one hour after tetracosactide adminis-
tration. Patient data are included in Table 1. All tested indi-
viduals have been eventually found to be free from any func-
tional disturbance of the hypothalamic-pituitary-adrenal
axis. The study was approved by the Ethical Committee
of the Hungarian Health Council and informed written
consent was obtained from all patients involved.
2.2. RNA Isolation andReal-TimeReverse TranscriptionQuan-
titative Polymerase Chain Reaction (RT-qPCR) from Plasma
Samples. RNA isolation has been performed as described in
our previous study [10]. Briefly, EDTA-anticoagulated blood
was taken from patients and centrifuged at 3000 rpm for 20
minutes at 4∘C. All extracted plasma samples were stored at
−80∘C until further processing.
Total RNA was isolated from 200𝜇L plasma with Qiagen
miRNeasy Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s protocol with minor mod-
ifications, as described earlier [10]. RNA concentration was
measured by NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific Inc., Waltham, MA, USA), and the quality
and quantity were determined by anAgilent 2100 Bioanalyzer
(Agilent Tech. Inc., Santa Clara, CA, USA). RNA Integrity
(RIN) numbers of RNA isolated from plasma samples were
low (around 2.0), that is, similar to reported findings on RNA
isolated from blood [14]. RNA was stored at −80∘C until use.
10 ng of total RNA was reverse transcribed with TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA) and the specific looped RT primer. RT-
qPCR was performed by TaqMan Fast Universal PCRMaster
Mix (2x) (Applied Biosystems) on a 7500 Fast Real-Time PCR
System (Applied Biosystems) according to themanufacturer’s
protocol. The following probes have been used: hsa-miR-
27a (000408), hsa-miR-200b (002251), hsa-miR-214 (002306),
hsa-miR-483-5p (002338), hsa-miR-503 (001048), and cel-
miR-39 (000200) as reference gene [15]. Samples were run in
triplicate.
2.3. In Vitro Treatment of NCI-H295R Cells with Dexametha-
sone. The NCI-H295R adrenocortical carcinoma cell line
was purchased from the American Type Culture Collection
and maintained in the recommended media. For treatments,
hormone-free fetal bovine serum (FBS) was prepared as
follows: 0.1 g dextran coated charcoal (C6241, Sigma-Aldrich,
St. Louis, MO) was added to 6mL FBS and incubated for
24 h at 4∘C. Then the mixture was centrifuged at 3000×g for
10min and the supernatant was filtered through a 0.22𝜇m
filter. Cells were seeded on 6-well plates as 106 cells/well
using media containing 2.5% hormone-free FBS. Next day,
cells were synchronized by serum starvation for 24 h. On
the following day, 2.5% hormone-free FBS was added in the
presence of 100 nMdexamethasone or vehicle (DMSO). After
8 h incubation, cells and supernatans were harvested and
total RNA was extracted. Dexamethasone treatments were
repeated four times.
Total RNA was extracted using miRNeasy Mini Kit
(Qiagen) both from cells and culture medium according
to the manufacturer’s protocol with minor modifications,
as described earlier [16]. RNA concentration was measured
by NanoDrop 1000 Spectrophotometer (Thermo Fisher Sci-
entific Inc.). RIN numbers determined by an Agilent 2100
Bioanalyzer (Agilent Tech. Inc., Santa Clara, CA,USA) varied
between 9.0 and 10.0. RNAwas stored at −80∘C until use. RT-
qPCR reactions were performed by Taqman miRNA Assays
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Table 1: Characteristics of patients.
(a) Dexamethasone test
Patient
number
Gender
F/M
Age
(year) Disease/indication for testing
Baseline plasma
cortisol (𝜇g/dL)
Cortisol after
1mgDex (𝜇g/dL)
1 F 73 Obesity 12.6 1.6
2 F 30 Obesity, hirsutism 19.5 0.5
3 M 65 Obesity 10.7 0.9
4 M 45 Hypertension 17.4 0.9
5 F 61 Obesity, hypertension 9.4 1.6
6 F 68 Adrenal incidentaloma 13.5 1.8
7 M 65 Adrenal incidentaloma 25.6 1.7
8 M 68 Adrenal incidentaloma 19.4 1.7
9 M 59 Adrenal incidentaloma 17.6 1.8
10 F 20 Obesity 20.0 1.3
(b) Tetracosactide test
Patient
number
Gender
F/M
Age
(year) Disease/indication for testing
Baseline plasma
cortisol (𝜇g/dL)
Cortisol after 250 𝜇g
tetracosactide (𝜇g/dL)
1 F 30 Sec. amenorrhea 14.4 35.8
2 F 46 Suspicion for AI 6.6 20.7
3 F 36 Weakness 13.4 31.4
4 F 23 Raromenorrhoea 16.3 33.9
5 F 36 Infertility 7.2 29.5
6 F 37 Sec. amenorrhea 14.2 35.4
7 F 34 Raromenorrhoea 26.0 35.7
8 F 23 Hirsutism 16.0 32.3
9 M 60 Suspicion for AI 15.4 28.0
10 F 23 Infertility 11.0 34.4
AI: adrenal insufficiency.
(Applied Biosystems) using specific primer/probe combi-
nations: hsa-miR-27a (000408) and cel-miR-39 (000200) as
reference gene [15].
2.4. Statistical Analysis. To identify microRNAs showing
significant expression changes, Student’s 𝑡-test or Mann-
Whitney𝑈 test was used depending on the results of Shapiro-
Wilks normality test [10]. Data were expressed as ΔCt; thus
higher ΔCt indicates lower expression, whereas lower ΔCt
shows higher expression. Statistical analysis of RT-qPCR data
was done by Statistica 7.0 (StatSoft Inc., Tulsa, OK, USA)
software.
3. Results
3.1. Expression of Circulating MicroRNAs in Dexamethasone
and ACTH Stimulation Tests In Vivo. From the five microR-
NAs selected, only one circulating microRNA, hsa-miR-27a,
turned out to be significantly modulated by dexamethasone
and tetracosactide treatment in our study. Most interestingly,
dexamethasone and tetracosactide treatments resulted in
opposite changes of hsa-miR-27a expression as dexametha-
sone upregulated its plasma level, whereas tetracosactide
suppressed its expression (Figures 1 and 2).
The expression of hsa-miR-503 proved to be so low in
the plasma samples that we have decided to exclude it from
further analysis (data not shown).We have not found any cor-
relation between the changes of cortisol levels and circulating
microRNAs neither in the dexamethasone nor in the tetra-
cosactide tests (data not shown). There has been no correla-
tion between basal hsa-miR-27 levels and body weight either.
To confirm the dexamethasone responsiveness of hsa-
miR-27a, we have performed in vitro experiments on the
adrenocortical NCI-H295R cell line. We have observed dex-
amethasone responsiveness in vitro, as well. Dexametha-
sone significantly induced secreted hsa-miR-27a expression
in NCI-H295R culture medium (Figure 3). Dexamethasone
induced intracellular hsa-miR-27a in NCI-H295R cells too,
but this has not reached statistical significance (data not
shown). These results demonstrate that hsa-miR-27a is
secreted by NCI-H295R cells and the level of secreted hsa-
miR-27a is induced by dexamethasone, as well.
4. Discussion
Wehave found that the expression of circulating hsa-miR-27a
is modulated by hormonal treatments in vivo in humans, as
its expression is induced by dexamethasone and suppressed
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Figure 1: Expression change of microRNAs in plasma after 1mg
overnight dexamethasone test normalized to cel-mir-39. ΔCt values
are represented: increased ΔCt indicates lower expression, whereas
decreased ΔCt indicates higher expression (mean ± SD). ∗𝑝 < 0.05,
𝑛 = 10. 𝑡-test was performed following the Shapiro-Wilks normality
test.
by ACTH. Dexamethasone induced secreted hsa-miR-27a
in vitro, as well. The expression of the most promising
circulating microRNAmarker of adrenocortical malignancy,
hsa-miR-483-5p, was not affected by these treatments also
used as diagnostic tests supporting its applicability as a
biomarker.
Circulating microRNAs are promising biomarkers in
several diseases including tumors and atherosclerosis [17].
There are some data that their levels might be affected by
hormonal changes, for example, in patients suffering from
polycystic ovarian syndrome, the serum concentration of
fourmicroRNAs appeared to be in part correlatedwith serum
free testosterone concentration [8].
To the best of our knowledge, the association of cir-
culating microRNAs and the hormonal actions affecting
the hypothalamic-pituitary-adrenal axis in vivo has not
been explored in humans, yet. Some circulating microRNAs
have been proposed as useful biomarkers for prediction of
malignancy of adrenocortical tumors [9–11]. Since adreno-
cortical cancer is frequently associated with adrenocortical
hormone overproduction [18, 19], the potential association of
hypothalamic-pituitary-adrenal axis functioning and circu-
latingmicroRNA levelsmight also be of interest. However, no
data about the expression changes of circulating microRNAs
during dexamethasone or ACTH-tests have been presented
to date.
We have selected five circulatingmicroRNAs for studying
their responsiveness to dexamethasone and ACTH adminis-
tration in vivo. Among these, hsa-miR-214, hsa-miR-503, and
hsa-miR-483-5p have been proposed as tissue biomarkers for
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Figure 2: Expression change of microRNAs in plasma after 250 𝜇g
tetracosactide test, normalized to cel-mir-39. ΔCt values are repre-
sented: increasedΔCt indicates lower expression, whereas decreased
ΔCt indicates higher expression (mean ± SD). ∗𝑝 < 0.05, 𝑛 = 10.
Results of Mann-Whitney 𝑈 test.
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Figure 3: Expression change of secreted hsa-miR-27a after 100 nM
dexamethasone treatment for 8 hours in the NCI-H295R adreno-
cortical cell line mediums normalized to cel-mir-39. ΔCt values
are represented: increased ΔCt indicates lower expression, whereas
decreased ΔCt indicates higher expression (mean ± SD). ∗𝑝 < 0.05,
𝑛 = 4. Results of 𝑡-test.
adrenocortical malignancy [20–22], and hsa-miR-483-5p has
been found to be significantly overexpressed in blood samples
of adrenocortical cancer patients, as well [9–11]. Moreover,
the tissue expression ofmiR-214 andmiR-503was downregu-
lated by ACTH in a rat model [7]. Two further microRNAs
reported to be responsive to hormonal treatments in a rat
model were included in our study: the expression of both hsa-
miR-27a and hsa-miR-200b was shown to be downregulated
by dexamethasone, whereas ACTH also downregulated hsa-
miR-27a in rat adrenals [7].
The expression of the five selected circulatingmicroRNAs
has been studied in vivo using plasma samples of ten patients
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before and after low-dose dexamethasone testing and samples
from ten patients before and after tetracosactide adminis-
tration. All individuals included turned out to be eventually
free from any functional abnormality of the hypothalamic-
pituitary-adrenal axis.
From the microRNAs selected, only hsa-miR-27 turned
out to be significantly modulated by hormonal treatments in
vivo. The expression of the other four circulating microRNAs
that were shown to be associated with the adrenal was not
affected by dexamethasone or ACTH-administration. The
stable expression of circulating hsa-miR-483-5p not affected
by these hormones supports its applicability as a biomarker
of adrenocortical cancer. Our study has certainly limitations,
since healthy individuals were tested, and a different response
in ACC patients cannot be excluded.
Dexamethasone and tetracosactide treatments resulted in
opposite changes of hsa-miR-27a expression as dexametha-
sone upregulated its plasma levels, whereas tetracosactide
suppressed its expression (Figures 1 and 2). In addition,
secreted hsa-miR-27a was significantly induced by dexam-
ethasone treatment in vitro in theNCI-H295R adrenocortical
cell line as well. Our findings in culture medium underline
that dexamethasone induces the secretion of hsa-miR-27a
from adrenocortical cells (Figure 3). The molecular mech-
anism of hsa-miR-27a secretion in NCI-H295R cells and
its interaction with dexamethasone, however, awaits further
studies. In a rat model, ACTH-treatment also suppressed
tissuemiR-27a expression, but dexamethasone did the same.
This discrepancy might be related to species differences;
moreover, the expression of tissue and circulating microR-
NAs can be different [11].
The in vitro and in vivo action of dexamethasone on hsa-
miR-27a expression is similar, since it upregulated hsa-miR-
27a expression in both NCI-H295R adrenocortical cells in
vitro (both cellular and secreted) and circulating hsa-miR-
27a in vivo. The cellular origin of circulating microRNAs
is, however, unclear, but these parallel changes in expres-
sion might raise the possibility of its partial adrenocortical
origin. There are several data underlining the relevance
of hsa-miR-27a in muscles, angiogenesis, adipogenesis and
obesity, inflammation, immune response, lipid metabolism,
atherosclerosis, and metabolic syndrome [23]. Circulating
hsa-miR-27a has been raised as a biomarker for left ventric-
ular contractility after acute myocardial infarction [24] and
hypertrophic cardiomyopathy [25], and it was found to be
underexpressed in early stage non-small cell lung cancer [26].
All these tissues are targets for glucocorticoid actions
mediated via the glucocorticoid receptor. Since dexametha-
sone treatment also altered hsa-miR-27a expression in the
NCI-H295R adrenocortical cell line, itmight be hypothesized
that this microRNA may be also regulated via the gluco-
corticoid receptor. As the transcription of hsa-miR-27a is
made by RNA Polymerase II [27] it would be interesting to
test whether a functional glucocorticoid response element is
present in the hsa-miR-27a promoter (by in silico prediction,
a glucocorticoid response element can be localized within the
hsa-miR-27a promoter (data not shown)).
hsa-miR-27a has been shown to downregulate myostatin
expression that is a major growth factor implicated in muscle
development and muscle atrophy. Increased myostatin ex-
pression was associated with muscle wasting [28]. miR-27a
and myostatin appear to be involved in an autoregulatory
loop as myostatin increases miR-27a expression via SMAD3
and miR-27a in turn inhibits myostatin expression in a
murine model [28]. As glucocorticoids inhibit the transcrip-
tional activation of SMAD3 [29], administration of dexam-
ethasone might interfere with the myostatin-SMAD3-miR-
27a loop atmultiple points.TheACTH-induced downregula-
tion of circulating hsa-miR-27a might also be relevant,
for example, in ACTH-dependent Cushing’s syndrome. The
overall effects of these actions on myostatin, miR-27a, and
SMAD3 would be difficult to predict at present, but these
findingsmight be implicated in the pathogenesis of glucocor-
ticoid-induced muscle atrophy characteristic for hypercorti-
solism.
Levels of circulating hsa-miR-27a have been found to
be strongly associated with fasting glucose levels and type
2 diabetes mellitus [30]. Since glucocorticoids are involved
in the pathogenesis of insulin resistance [31], these findings
raise the possibility that ACTH- and glucocorticoid-induced
changes in hsa-miR-27a expression might be relevant in the
pathogenesis of various diseases, and most of all in hyper-
cortisolism, but further studies are needed to establish the
pathological relevance of these alterations.
5. Conclusions
By analyzing the expression of selected microRNAs based
on literature data, we have established that hsa-miR-27a is
significantly downregulated by ACTH and induced by dexa-
methasone-treatment in vivo. We have also observed the in
vitro induction of secreted hsa-miR-27a in adrenocortical
NCI-H295R cells by dexamethasone. The expression of hsa-
miR-483-5p proposed as a biomarker of ACCwas not affected
by hormonal treatments that underlines its applicability as
a potential diagnostic test in the preoperative diagnosis of
ACC. These data together highlight again that microRNAs
are present in the circulation, and some of these are targets
for hormone actions, and similarly to the hormone con-
centration measurement, strict preanalytical and analytical
conditions should be followed before sampling.
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